Food, drugs, devices › Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center
Drug recall: PF-Succinylcholine Chloride Injection, USP 20 mg/mL (200 mg/10 mL), Rx Only, Single-Dose Container, 5 x 10 mL pre-filled
Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center (West Columbia, SC) initiated this drug recall on 21 Oct 2019; FDA lists 1 product record under event 84106, classified Class III.
FDA defines Class III as a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences. 22% of the 362 drug enforcement events initiated in 2019 carry the same class.
Status: Terminated, terminated 7 May 2020. Initiation: voluntary: firm initiated. Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center has 3 enforcement events on this register, with a median of 2 product records per event.
Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.
Recalling firm
Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, West Columbia, SC.
Reason for recall
"Incorrect labeling: Incorrect or missing lot and/or exp date"
Distribution
"Nationwide in the U.S."
Product records
| Recall number | Product | Quantity | Class | Status | Report date |
|---|---|---|---|---|---|
| D-0154-2020 | PF-Succinylcholine Chloride Injection, USP 20 mg/mL (200 mg/10 mL), Rx Only, Single-Dose Container, 5 x 10 mL pre-filled syringes, Nephron 503B Outsourcing Facility 4500 12th St. Ext West Columbia, SC 29172, NDC 69374-919-10. | 19,390 syringes | Class III | Terminated | 6 Nov 2019 |
Context
Other enforcement events for Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center
| Initiated | Product (first record) | Type | Class | Records |
|---|---|---|---|---|
| 9 Oct 2019 | PF-Fentanyl Citrate (2 mcg/mL)* & Bupivacaine HCl 0.0625 in 0.9% Sodium Chloride Injection-250 mL Total Dose: (500 mcg/1 | Drug | Class II | 3 |
| 9 Oct 2019 | Amino Acid Injection 50 g/1000 mL (50 mg/mL) 25 g L-Arginine HCl; 25 g L-Lysine HCl, Single Dose Container, Rx Only Neph | Drug | Class II | 2 |
All 3 events for Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center
Questions and answers
Why was this drug recalled?
FDA's record gives the reason for recall as: "Incorrect labeling: Incorrect or missing lot and/or exp date"
What does Class III mean?
FDA classifies recalls by relative degree of health hazard. Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
Where was the product distributed?
FDA's distribution pattern field reads: "Nationwide in the U.S."
Is the recall still ongoing?
FDA lists the status as Terminated; the termination date is 7 May 2020. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.
Where does this data come from?
openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.
Provenance
Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.